|
Cause of Pigment Dispersion Syndrome Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on Cause of Pigment Dispersion Syndrome conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Cause of Pigment Dispersion Syndrome Clinical research trials and Cause of Pigment Dispersion Syndrome healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including Cause of Pigment Dispersion Syndrome. Cause of Pigment Dispersion Syndrome Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Cause of Pigment Dispersion Syndrome clinical trial. Test subjects oftentimes recieve the best healthcare possible for their Cause of Pigment Dispersion Syndrome condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Cause of Pigment Dispersion Syndrome  Cause of Pigment Dispersion Syndrome
Cause of Pigment Dispersion Syndrome
For Condition: Pigment Dispersion Syndrome,Healthy,Glaucoma
Status: Completed
Sponsor(s): National Eye Institute (NEI) ,
Synopsis: The purpose of this study is to learn how pigment is released from the iris (the colored part of the eye) in patients with pigment dispersion syndrome. It will do this by examining the response of the pupil (the central opening of the iris) to a flash of light to determine what is happening in the iris to cause release of the pigment. In pigment dispersion syndrome, pigment released from the iris is deposited in other parts of the eye, including the trabecular meshwork-a filter-like tissue in the front of the eye. Aqueous fluid (fluid continuously produced by the eye) normally flows out of the eye through the trabecular meshwork. In some patients, the pigment deposits may block tiny holes in the meshwork, preventing the fluid from flowing out. This can cause an increase in eye pressure that may lead to glaucoma and some loss of vision. Understanding how pigment is released from the iris may help predict the course of pigment dispersion syndrome and identify which patients will likely develop increased eye pressure. Patients with pigment dispersion syndrome and normal volunteers may be eligible for this study. All participants will have the following procedures, which will be completed in two clinic visits: First visit 1. Examination of the front of the eyes, including the cornea, iris and lens. 2. Vision testing and measurements of visual field and eye pressure. 3. Examination of the trabecular meshwork. For this test, a contact lens is placed on the eye after the eye has been numbed with anesthetic drops. Second visit 1. Refraction (dilation of the pupils with drops) and examination of the back of the eyes, including the optic nerve. 2. Reaction of the pupils to low-level infrared light (pupillography). During this 15-minute test, the patient or volunteer wears a lightweight headband with two small cameras mounted on it. The cameras-one which views the eye and the other the subject's field of view-record pupil dilation and position. The test results in patients with pigment dispersion syndrome will be compared with those in normal volunteers. Patients will be followed every 6 months (or more often, if medically indicated) during the 3-year study to determine changes in eye pressure or visual field. Volunteers will be asked to return about once a year for 3 years for repeat pupillography.
Details: The purpose of this study is to conduct a comprehensive ophthalmologic evaluation and comparison of two types of patients and to compare them to normal controls. The two types of patients are those with pigment dispersion (PDS) with normal intraocular pressure (IOP) and those with PDS and elevated IOP. The hypothesis to be tested is that a developmental abnormality of the iris pigment epithelium (IPE) and the dilator muscle is the fundamental defect responsible for the pigment dispersion. This defect may involve other structures of the eye such as the ciliary and retinal pigment epithelium. The results of pupillography in PDS with or without elevated IOP and asymmetric PDS (one eye versus fellow eye) will be the outcome parameters.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: All patients entering the study must have black pigment deposition on the trabecular meshwork at the site of Schlemm's canal equal to or greater than 2-plus on the goniophotographic scale of 1 to 5 plus. Although this condition is rare amongst African-Americans, every effort will be made to recruit such individuals. EXCLUSION CRITERIA: Patients with exfoliation syndrome, uveitis, trauma, pigment dispersion with posterior chamber intra-ocular lens, pigmented tumors, primary open-angle glaucoma, other conditions with associated pigment dispersion such as acute angle-closure glaucoma, ocular hemorrhage, Horner's syndrome. In addition, normal volunteers will be recruited as controls. They will be free of any eye disease and be matched for age, sex and degree of myopia.
Total Enrollment: 90
Location and Contact Information:
National Eye Institute (NEI)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 000155; 00-EI-0155
Study Start Date: June 15, 2000
Record last reviewed: August 14, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005919
Other Glaucoma Studies:
1. Ocular Hypertension Treatment Study (OHTS)
2. Mechanism of Action of TRAVATAN 0.004% in Subjects with Glaucoma or Ocular Hypertension
3. Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients with Glaucoma or Ocular Hypertension.
4. Pigment Dispersion Syndrome With and Without Glaucoma
5. Advanced Glaucoma Intervention Study (AGIS)
Related Studies:
Other Glaucoma Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Cause of Pigment Dispersion Syndrome
|
|
|
|
|
|
|
|
